| (Original Signature of Member) |
|--|
| 116TH CONGRESS 2D SESSION H. R. |
| To direct the Secretary of Veterans Affairs to establish or update certain clinical practice guidelines of the Department of Veterans Affairs, and for other purposes. |
| |
| IN THE HOUSE OF REPRESENTATIVES |
| Mr. CISNEROS introduced the following bill; which was referred to the Committee on |
| |
| A BILL |
| To direct the Secretary of Veterans Affairs to establish or |

To direct the Secretary of Veterans Affairs to establish or update certain clinical practice guidelines of the Department of Veterans Affairs, and for other purposes.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Setting Treatment Op-
- 5 tions and Practices for Veteran Suicide and Substance
- 6 Abuse Act" or the "STOP Veteran Suicide and Substance
- 7 Abuse Act".

| 1 | SEC. 2. ESTABLISHMENT BY DEPARTMENT OF VETERANS |
|----|--|
| 2 | AFFAIRS AND DEPARTMENT OF DEFENSE OF |
| 3 | CLINICAL PRACTICE GUIDELINES FOR CO- |
| 4 | MORBID MENTAL HEALTH CONDITIONS SUCH |
| 5 | AS PTSD, MST, AND/OR TBI. |
| 6 | (a) In General.—Not later than two years after the |
| 7 | date of the enactment of this Act, the Secretary of Vet- |
| 8 | erans Affairs, in consultation with the Secretary of De- |
| 9 | fense and the Secretary of Health and Human Services, |
| 10 | shall complete the development of clinical practice guide- |
| 11 | lines for the treatment of post-traumatic stress disorder, |
| 12 | military sexual trauma, and traumatic brain injury that |
| 13 | is comorbid with substance use disorder or chronic pain. |
| 14 | (b) Work Group.— |
| 15 | (1) Establishment.—In carrying out sub- |
| 16 | section (a), the Secretary of Veterans Affairs, the |
| 17 | Secretary of Defense, and the Secretary of Health |
| 18 | and Human Services shall create a Trauma and Co- |
| 19 | morbid Substance Use Disorder or Chronic Pain |
| 20 | Work Group (in this section referred to as the |
| 21 | "Work Group"). |
| 22 | (2) Membership.—The work group created |
| 23 | under paragraph (1) shall be comprised of individ- |
| 24 | uals that represent Federal Government entities and |
| 25 | non-Federal Government entities with expertise in |

| 1 | the areas covered by the work group, including the |
|----|---|
| 2 | following: |
| 3 | (A) Academic institutions that specialize in |
| 4 | research for the treatment of conditions de- |
| 5 | scribed in subsection (a). |
| 6 | (B) The National Center for Posttraumatic |
| 7 | Stress Disorder of the Department of Veterans |
| 8 | Affairs. |
| 9 | (C) The Office of the Assistant Secretary |
| 10 | for Mental Health and Substance Use of the |
| 11 | Department of Health and Human Services. |
| 12 | (3) Relation to other work groups.—The |
| 13 | Work Group shall be created and conducted in the |
| 14 | same manner as other work groups for the develop- |
| 15 | ment of clinical practice guidelines for the Depart- |
| 16 | ment of Veterans Affairs and the Department of De- |
| 17 | fense. |
| 18 | (c) Matters Included.—In developing the clinical |
| 19 | practice guidelines under subsection (a), the Work Group, |
| 20 | in consultation with the Post Traumatic Stress Disorder |
| 21 | Work Group, Concussion-mTBI Work Group, Opioid |
| 22 | Therapy for Chronic Pain Work Group, and Substance |
| 23 | Use Work Group, shall ensure that the clinical practice |
| 24 | guidelines include the following: |
| 25 | (1) Guidance with respect to the following: |

| 1 | (A) The treatment of patients with post- |
|----|---|
| 2 | traumatic stress disorder who are also experi- |
| 3 | encing a substance use disorder or chronic pain. |
| 4 | (B) The treatment of patients experiencing |
| 5 | a mental health condition, including anxiety, de- |
| 6 | pression, or post-traumatic stress disorder as a |
| 7 | result of military sexual trauma who are also |
| 8 | experiencing a substance use disorder or chron- |
| 9 | ie pain. |
| 10 | (C) The treatment of patients with trau- |
| 11 | matic brain injury who are also experiencing a |
| 12 | substance use disorder or chronic pain. |
| 13 | (2) Guidance with respect to the following: |
| 14 | (A) Appropriate case management for pa- |
| 15 | tients experiencing post-traumatic stress dis- |
| 16 | order that is comorbid with substance use dis- |
| 17 | order or chronic pain who transition from re- |
| 18 | ceiving care while on active duty in the Armed |
| 19 | Forces to care from health care networks out- |
| 20 | side of the Department of Defense. |
| 21 | (B) Appropriate case management for pa- |
| 22 | tients experiencing a mental health condition, |
| 23 | including anxiety, depression, or post-traumatic |
| 24 | stress disorder as a result of military sexual |
| 25 | trauma that is comorbid with substance use dis- |

| 1 | order or chronic pain who transition from re- |
|----|---|
| 2 | ceiving care while on active duty in the Armed |
| 3 | Forces to care from health care networks out- |
| 4 | side of the Department of Defense. |
| 5 | (C) Appropriate case management for pa- |
| 6 | tients experiencing traumatic brain injury that |
| 7 | is comorbid with substance use disorder or |
| 8 | chronic pain who transition from receiving care |
| 9 | while on active duty in the Armed Forces to |
| 10 | care from health care networks outside of the |
| 11 | Department of Defense. |
| 12 | (3) Guidance with respect to the treatment of |
| 13 | patients who are still members of the Armed Forces |
| 14 | and are experiencing a mental health condition, in- |
| 15 | cluding anxiety, depression, or post-traumatic stress |
| 16 | disorder as a result of military sexual trauma that |
| 17 | is comorbid with substance use disorder or chronic |
| 18 | pain. |
| 19 | (4) Guidance with respect to the assessment by |
| 20 | the National Academies of Sciences, Engineering, |
| 21 | and Medicine of the potential overmedication of vet- |
| 22 | erans, as required pursuant to the Senate report ac- |
| 23 | companying S. 1557, 115th Congress (Senate Re- |
| 24 | port 115-130), under the heading "Overprescription |

| 1 | Prevention Report" under the heading "COMMITTEE |
|----|--|
| 2 | RECOMMENDATION". |
| 3 | (d) Rule of Construction.—Nothing in this sec- |
| 4 | tion shall be construed to prevent the Secretary of Vet- |
| 5 | erans Affairs and the Secretary of Defense from consid- |
| 6 | ering all relevant evidence, as appropriate, in creating the |
| 7 | clinical practice guidelines required under subsection (a) |
| 8 | or from ensuring that the final clinical practice guidelines |
| 9 | developed under such subsection and subsequently up- |
| 10 | dated, as appropriate, remain applicable to the patient |
| 11 | populations of the Department of Veterans Affairs and the |
| 12 | Department of Defense. |
| 13 | SEC. 3. UPDATE OF CLINICAL PRACTICE GUIDELINES FOR |
| 14 | ASSESSMENT AND MANAGEMENT OF PA- |
| 15 | TIENTS AT RISK FOR SUICIDE BY TAKING |
| 16 | INTO CONSIDERATION GENDER- AND AGE- |
| 17 | SPECIFIC RISK FACTORS AND GENDER- AND |
| 18 | AGE-SPECIFIC TREATMENT EFFICACY OF |
| 19 | PHARMACOTHERAPY AND PSYCHOTHERAPY. |
| 20 | (a) IN GENERAL.—Not later than two years after the |
| 21 | date of the enactment of this Act, the Secretary of Vet- |
| 22 | erans Affairs and the Secretary of Defense, through the |
| 23 | Assessment and Management of Patients at Risk for Sui- |
| 24 | cide Work Group (in this section referred to as the "Work |
| 25 | Group"), shall issue an update to the VA/DOD Clinical |

| 1 | Practice Guideline for Assessment and Management of |
|----|--|
| 2 | Patients at Risk for Suicide. |
| 3 | (b) Matters Included.—In carrying out the up- |
| 4 | date under subsection (a), the Work Group shall ensure |
| 5 | that the clinical practice guidelines updated under such |
| 6 | subsection includes the following: |
| 7 | (1) Enhanced guidance with respect to the fol- |
| 8 | lowing: |
| 9 | (A) Gender- and age-specific risk factors |
| 10 | for suicide and suicidal ideation. |
| 11 | (B) Gender- and age-specific treatment ef- |
| 12 | ficacy for depression and suicide prevention. |
| 13 | (C) Gender- and age-specific |
| 14 | pharmacotherapy efficacy. |
| 15 | (D) Gender- and age-specific psycho- |
| 16 | therapy efficacy. |
| 17 | (2) Guidance with respect to the efficacy of al- |
| 18 | ternative therapies, other than psychotherapy and |
| 19 | pharmacotherapy, including the following: |
| 20 | (A) Yoga therapy. |
| 21 | (B) Meditation therapy. |
| 22 | (C) Equine therapy. |
| 23 | (D) Other animal therapy. |
| 24 | (E) Training and caring for service dogs. |
| 25 | (F) Agri-therapy. |

| 1 | (G) Art therapy. |
|----|--|
| 2 | (H) Outdoor sports therapy. |
| 3 | (I) Music therapy. |
| 4 | (J) Any other alternative therapy that the |
| 5 | Work Group considers appropriate. |
| 6 | (3) Guidance with respect to the findings of the |
| 7 | Creating Options for Veterans' Expedited Recovery |
| 8 | Commission (commonly referred to as the "COVER |
| 9 | Commission") established under section 931 of the |
| 10 | Jason Simcakoski Memorial and Promise Act (title |
| 11 | IX of Public Law 114–198; 38 U.S.C. 1701 note). |
| 12 | (e) Rule of Construction.—Nothing in this sec- |
| 13 | tion shall be construed to prevent the Secretary of Vet- |
| 14 | erans Affairs and the Secretary of Defense from consid- |
| 15 | ering all relevant evidence, as appropriate, in updating the |
| 16 | VA/DOD Clinical Practice Guideline for Assessment and |
| 17 | Management of Patients at Risk for Suicide, as required |
| 18 | under subsection (a), or from ensuring that the final clin- |
| 19 | ical practice guidelines updated under such subsection re- |
| 20 | main applicable to the patient populations of the Depart- |
| 21 | ment of Veterans Affairs and the Department of Defense. |